Literature DB >> 1495787

Ocular surface alteration after long-term treatment with an antiglaucomatous drug.

J M Herreras1, J C Pastor, M Calonge, V M Asensio.   

Abstract

BACKGROUND: This study was undertaken to see whether long-term locally applied ocular medications produced any alterations in the ocular surface, and, in particular, whether it caused damage to the mucus layer of the tear film.
METHODS: The authors studied the ocular surface of 40 control subjects (group 1), 21 patients (group 2) chronically treated with a commercial preparation of 0.5% timolol maleate, and 20 previously untreated glaucomatous patients (group 3) in need of treatment with the same drug. Parameters studied were Schirmer's test, lacrimal meniscus height, break-up time, fluorescein and rose Bengal stains, conjunctival impression cytology, mucus staining, and the ferning test.
RESULTS: Patients in groups 2 and 3 showed a significant decrease (P less than 0.001) in the number of normal Schirmer's and break-up time tests. All had positive vital stains. Results showed a significant decrease (P less than 0.001) in goblet-cell density, mucus granules, and reticular sheets, and an increase (P less than 0.001) in pathologic crystallization patterns.
CONCLUSION: These results demonstrate that chronic application of a commercial preparation of timolol maleate damaged the ocular surface, especially the mucus layer of the tear film.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495787     DOI: 10.1016/s0161-6420(92)31847-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  53 in total

1.  Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response.

Authors:  R Nuzzi; C Finazzo; A Cerruti
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

2.  Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.

Authors:  J Shimazaki; K Hanada; Y Yagi; J Yamagami; M Ishioka; S Shimmura; K Tsubota
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

3.  [Glaucoma and corneal transplantation].

Authors:  G Geerling; M Müller; M Zierhut; T Klink
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

4.  Effects of long-term topical anti-glaucoma medications on meibomian glands.

Authors:  Reiko Arita; Kouzo Itoh; Shuji Maeda; Koshi Maeda; Ayumu Furuta; Atsuo Tomidokoro; Makoto Aihara; Shiro Amano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-18       Impact factor: 3.117

5.  Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment.

Authors:  Lorena Romero-Díaz de León; Jorge-Emmanuel Morales-León; Jasbeth Ledesma-Gil; Alejandro Navas
Journal:  Int Ophthalmol       Date:  2015-08-14       Impact factor: 2.031

6.  CA 19-9 ELISA test: a new method for studying mucus changes in tears.

Authors:  C Garcher; A Bron; C Baudouin; L Bildstein; J Bara
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

7.  Characterization of the Corneal Subbasal Nerve Plexus in Limbal Stem Cell Deficiency.

Authors:  Pichaya Chuephanich; Chantaka Supiyaphun; Carolina Aravena; Tahir Kansu Bozkurt; Fei Yu; Sophie X Deng
Journal:  Cornea       Date:  2017-03       Impact factor: 2.651

8.  Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications.

Authors:  Takeo Fukuchi; Kimiko Wakai; Kieko Suda; Tomoko Nakatsue; Hideko Sawada; Hiroaki Hara; Jun Ueda; Takayuki Tanaka; Akiko Yamada; Haruki Abe
Journal:  Clin Ophthalmol       Date:  2010-04-26

10.  Effect of latanoprost and timolol on the histopathology of the human conjunctiva.

Authors:  N Terai; U Schlötzer-Schrehardt; J Lampel; A G Böhm; C Rummelt; E Schmidt; L E Pillunat
Journal:  Br J Ophthalmol       Date:  2008-10-29       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.